奥密克戎流行期间住院 COVID-19 血液透析患者严重程度和死亡率的预测标志物。
The predictive markers of severity and mortality in hospitalized hemodialysis patients with COVID-19 during Omicron epidemic.
机构信息
Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.
Kidney Disease and Dialysis, Akane-Foundation, Ajina Tsuchiya Hospital, Hatsukaichi, Japan.
出版信息
Ther Apher Dial. 2023 Aug;27(4):701-710. doi: 10.1111/1744-9987.13970. Epub 2023 Feb 5.
INTRODUCTION
Predictive markers and prognosis remain unclear in hospitalized hemodialysis (HD) patients with coronavirus disease 2019 (COVID-19) during the Omicron epidemic.
METHODS
We evaluated characteristics, laboratory parameters, and outcomes in hospitalized HD patients with COVID-19 (n = 102) at two centers between January and April 2022.
RESULTS
The 30-day mortality rate was higher in moderate-critical group (n = 43) than mild group (n = 59) (16.3% vs. 1.7%; p = 0.007), and higher in patients with lower CC chemokine ligand 17 (CCL17) levels (<95.0 pg/mL) compared with normal CCL17 levels (19.0% versus 4.9%; p = 0.03). In multivariate analyses, a low CCL17 level (p = 0.003) was associated with moderate-critical conditions, and moderate-critical conditions (p = 0.04) were associated with 30-day mortality, whereas CCL17 was not associated with 30-day mortality.
CONCLUSIONS
COVID-19 remains a fatal complication, and CCL17 was a predictive marker of severity in hospitalized HD patients during the Omicron epidemic.
简介
在奥密克戎流行期间，住院血液透析（HD）COVID-19 患者的预测标志物和预后仍不清楚。
方法
我们在 2022 年 1 月至 4 月期间在两个中心评估了 COVID-19 住院 HD 患者（n=102）的特征、实验室参数和结局。
结果
中危组（n=43）的 30 天死亡率高于轻症组（n=59）（16.3%比 1.7%；p=0.007），CCL17 水平较低（<95.0pg/ml）的患者高于 CCL17 水平正常的患者（19.0%比 4.9%；p=0.03）。多变量分析显示，低 CCL17 水平（p=0.003）与中危情况相关，中危情况（p=0.04）与 30 天死亡率相关，而 CCL17 与 30 天死亡率无关。
结论
COVID-19 仍然是一种致命的并发症，在奥密克戎流行期间，CCL17 是住院 HD 患者严重程度的预测标志物。
Zotero 插件